source
- Agios halts development of tebapivat for low-risk MDS after disappointing Phase 2b dataAgios Pharmaceuticals announced it will discontinue development of its pyruvate kinase activator tebapivat for patients with low-risk myelodysplastic syndromes (MDS). The decision follows the relea…
- FDA releases draft guidance to trim animal testing in cancer drug developmentThe FDA's Oncology Center of Excellence announced a draft guidance aimed at reducing unnecessary animal studies in the nonclinical safety assessment of certain oncology drugs. The guidance suggest…